Project Grant R00HL171869
Award Date 8/1/25
Completion Date 6/30/28
Dollars Obligated $249K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Indianapolis, IN 46202, USA
Similar Awards
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $175,392 to the University of California, Los Angeles (UCLA) to support the research of Dr. Adam J. Brownstein, a pulmonary and critical care physician. The goal of this 5-year award is to enable Dr. Brownstein to establish himself as an independent investigator in patient-oriented research on pulmonary hypertension associated with pulmonary fibrosis (PF-PH)....
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $715,161 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the Trustees of Indiana University, doing business as Indiana University Indianapolis (IU Indianapolis), to conduct research on the epigenetic regulation of pulmonary smooth muscle cell remodeling in pulmonary hypertension. The research aims to elucidate the molecular mechanisms by which the sphingosine kinase 2 (SPHK2) enzyme contributes to vascular...
- This federal Project Grant award of $522,794.00 was provided by the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), to the University of Illinois for a project titled "HV1 IN PULMONARY HYPERTENSION". The project aims to examine the role of the voltage-gated proton channel HV1 in the development and progression of pulmonary hypertension, a serious cardiovascular condition. The research will apply transgenic mouse...
- This Project Grant award of $143,819 from the National Heart, Lung, and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of the mitochondrial acid-sensing ion channel 1 (ASIC1A) in pulmonary hypertension. The project aims to define the mechanisms of ASIC1A trafficking and its impact on pulmonary arterial smooth muscle cell function, with the goal of identifying novel molecular targets to improve treatment for pulmonary...
- This Project Grant award of $170,640 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research at Vanderbilt University Medical Center (VUMC) to investigate a novel mechanism of apoptosis resistance in pulmonary arterial smooth muscle cells. The key objectives are to: 1) develop the grantee's skills to facilitate the transition to an independent clinician scientist focused on pulmonary vascular remodeling in pulmonary arterial...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $586,637 to the University of New Mexico (UNM) to conduct research into the mechanisms of immune dysregulation that contribute to the development of hypoxic pulmonary hypertension (PH). The research aims to identify how chronic hypoxia causes a decrease in regulatory T cells (Tregs) and promotes the development of self-reactive T helper 17 (Th17) cells that target...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $760,708 to investigate the role of alternative polyadenylation (APA) in right ventricular (RV) fibrosis associated with pulmonary hypertension. The research aims to: Investigate the impact of the APA regulator CPSF6 depletion on the 3' UTR landscape and profibrotic gene expression in RV failure. Uncover the mechanism underlying CPSF6...
- This Project Grant award from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports research to investigate the role of the kynurenine pathway metabolism in pulmonary arterial hypertension (PAH). The $514,484 award to The Johns Hopkins University will fund a 5-year research project to establish a prospective observational cohort of PAH patients and measure longitudinal changes in kynurenine pathway metabolites and...
- This Project Grant award from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research program (CFDA 93.837), provides $156,416 to investigate the role of the RASA3 gene in maintaining the health of pulmonary artery endothelial cells and its impact on pulmonary vascular disease. The research aims to identify how RASA3-mediated regulation of BMPR2 affects pulmonary vascular dysfunction and explore RASA3 as a potential therapeutic target for pulmonary arterial...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,385,536 to Rhode Island Hospital to conduct research on pulmonary arterial hypertension (PAH). The goal is to characterize endothelial cell (EC) dysfunction in PAH, with a focus on understanding the role of anoikis resistance - abnormal programmed cell death triggered by cell detachment from the vessel wall. The research will leverage a "cell...